Peer Review History

Original SubmissionMay 15, 2025
Decision Letter - Marwan Al-Nimer, Editor

Dear Dr.  Yu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 07 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Marwan Salih Al-Nimer, MD, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

3. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript.

4. Thank you for uploading your study's underlying data set. Unfortunately, the repository you have noted in your Data Availability statement does not qualify as an acceptable data repository according to PLOS's standards.

At this time, please upload the minimal data set necessary to replicate your study's findings to a stable, public repository (such as figshare or Dryad) and provide us with the relevant URLs, DOIs, or accession numbers that may be used to access these data. For a list of recommended repositories and additional information on PLOS standards for data deposition, please see https://journals.plos.org/plosone/s/recommended-repositories .

5. Please amend your manuscript to include your abstract after the title page.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

7. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 

Additional Editor Comments:

major revision

The authors

a few points need rephrasing and clarifications

1: The objectives of the study is focusing on the role of BMI as a mediator for the development of MetS. The conclusion in the abstract and at the end of discussion is free from this assumption

2: Typing errors, e.g., recheck Table 1

3: Explain the units of the eGDR formula, i.e., the unit kg is derived from....., min is derived from......

4: The results in the tables missed the "the data presented as median (IQR)".

5: The title of figures was typed as capitalized each word

6: The authors focused on the mediation (indirect) effect), why they did not use Sobel test, which is more accurate.

7: The typing of the references in the text and in the references section need to recheck.

[Note: HTML markup is below. Please do not edit.]

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: Thank you for the opportunity to review this manuscript. I have provided my detailed answers to the questions above in the space below. I found the study to be of high relevance and scientific value, and I have no concerns regarding dual publication, research ethics, or publication ethics at this time.

Reviewer #2: To improve transparency and reproducibility, the authors should be encouraged to provide a clear data availability statement, detailing how and where the dataset and code used for analysis (e.g., R scripts) can be accessed or requested.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: Yes:  Melchor Alpízar Salazar

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Attachments
Attachment
Submitted filename: Zhang et al., Higher Estimated Glucose Disposal Rate.pdf
Revision 1

Dear Editor and Reviewers,

We would like to express our sincere gratitude for your thoughtful comments and constructive suggestions on our manuscript entitled Estimated Glucose Disposal Rate and Risk of Metabolic Syndrome: A Population-Based Study. Your insightful feedback has been invaluable in guiding the improvement of our work. We deeply appreciate the time and effort you have invested in reviewing our manuscript. In response to your comments, we have made revisions to address each point raised. The changes made to the original manuscript are highlighted in red, and a detailed point-by-point response follows below.

Reviewer 1

Q1: The title is informative but could be refined slightly. Consider simplifying it for better clarity and flow, e.g.:

"Higher Estimated Glucose Disposal Rate Is Associated with Reduced Risk of Metabolic Syndrome: A Population-Based Study"

A1: Thank you very much for your valuable suggestion regarding the title. We have ultimately decided to adopt the following title: Estimated Glucose Disposal Rate and Risk of Metabolic Syndrome: A Population-Based Study. This title clearly conveys the core relationship between the exposure and the outcome, while also meeting the journal’s requirements for clarity and conciseness.

Q2: The abstract is clear and well-structured, but it slightly exceeds standard journal lengths. Consider shortening by focusing only on the most critical results and interpretations.

Line 30: “Spline regression analysis further revealed...” Consider removing "further" for conciseness unless referring back to a prior method.

Line 37: "suggesting individuals with low eGDR should monitor their potential..." This phrasing is slightly vague. Consider rewording to: "suggesting that individuals with low eGDR may benefit from closer monitoring for MetS development."

A2�Thank you very much for your careful review of my abstract and for providing such valuable suggestions. PLOS ONE requires that abstracts not exceed 300 words, and I have now reduced mine to 263 words, making it more concise. I have also revised Line 32 and Lines40-41 as suggested. I sincerely appreciate your hard work and thoughtful guidance on my manuscript.

Q3�Line 48–49: The phrase “Despite the limited availability of global data on MetS...” might be misleading since MetS prevalence is relatively well-documented globally.

A3�Thank you very much for your detailed suggestions. I realized that my original wording was inaccurate. After carefully reviewing the literature, I have revised the phrasing. It is now stated as: “Global estimates of MetS may vary due to differences in study design and population coverage, its prevalence is approximately three times that of diabetes, affecting roughly one-quarter of the global population, which corresponds to more than one billion individuals.” Thank you for your understanding.(Lines50-56)

Q4�Line 100: In the formula for eGDR, clarify the hypertension coding. Currently, it says "1 for yes and 2 for no," which might be an error. Standard binary coding is usually 1 = yes, 0 = no.

A4�I apologize for my oversight, and thank you for your reminder. I have corrected the error and included the corresponding reference.(Line105)

Q5: Line 151: “The study included a total of 3,229 participants with a mean age of 58 years.”Consider adding SD if available to clarify variation.

A5: We thank the reviewer for the valuable suggestion regarding the presentation of age. In the revised manuscript, we have updated the text to report the total participants’ age as mean ± standard deviation: “The study included a total of 3,229 participants with a mean age of 58.7 ± 8.8 years.”

We kept the age data in Table 1 as median (interquartile range), since the distribution of age is slightly skewed, and median (IQR) is more appropriate for summarizing the groups. We believe this approach addresses the reviewer’s comment while accurately reflecting the data.

We appreciate the reviewer’s careful reading and helpful comment.(Lines156, table1, Lines170-171)

Q6: Line 186: “the OR for the Q3 group was no longer significantly lower..." This needs clarification. The OR seems to be near 1.01 with a CI of [1.00–1.02], yet still has a significant P-value. Consider double-checking if this is an error or needs better explanation.

A6: Thank you for your careful observation and feedback. I apologize for my oversight and have revised the sentence accordingly.”In Model 2, after adjusting for different covariates, the OR for the Q3 group increased significantly to 1.01 (95% CI: 1.00–1.02), consistent with the findings in Model 3.”(Lines192-196)

Reviewer 2

Q1: The objectives of the study is focusing on the role of BMI as a mediator for the development of MetS. The conclusion in the abstract and at the end of discussion is free from this assumption

A1�We sincerely thank the reviewer for this insightful comment. In response, we have revised the conclusion of the abstract, the discussion section, and the final conclusion of the manuscript to explicitly highlight the mediating role of BMI in the relationship between eGDR and MetS. We greatly appreciate the reviewer’s careful consideration and constructive feedback, which have made our manuscript more professional and rigorous. Thank you again for your valuable efforts in improving our work.(Lines40-41, Lines289-303, Line322)

Q2: Typing errors, e.g., recheck Table 1

A2�Thank you for your careful observation. I apologize for my oversight. I have carefully reviewed and revised Table 1 to ensure it is more accurate, standardized, and complete.

Q3: Explain the units of the eGDR formula, i.e., the unit kg is derived from....., min is derived from......

A3�Thank you for this insightful comment. The eGDR formula was originally derived from regression models against the euglycemic–hyperinsulinemic clamp, which serves as the gold standard for insulin sensitivity measurement (expressed in mg/kg/min). In this equation, waist circumference is entered in centimeters, hypertension is coded as 1 for yes and 0 for no, and HbA1c is entered as a percentage. Because the regression coefficients were estimated against clamp data expressed in mg/kg/min, the final calculated eGDR values naturally inherit this unit. We have clarified this point in the revised manuscript and greatly appreciate the reviewer’s constructive suggestion.(Line106)

Q4: The results in the tables missed the "the data presented as median (IQR)".

A4�We sincerely thank the reviewer for the valuable suggestion regarding the presentation of continuous variables in Table 1. In the revised manuscript, we have updated the table footnote to clearly indicate that continuous variables are presented as median (interquartile range, IQR) or mean ± standard deviation (SD), depending on the distribution. We believe this revision improves the clarity and accuracy of the data presentation. We greatly appreciate the reviewer’s careful reading and helpful comment.(Lines170-171)

Q5: The title of figures was typed as capitalized each word

A5: Thank you very much for your careful review and valuable comments. I apologize for the oversight regarding the figure titles. Following your suggestion, I have revised all figure titles to sentence case and carefully rechecked the overall formatting of the manuscript to avoid similar issues. I sincerely appreciate your time and effort in reviewing my work.

Q6: The authors focused on the mediation (indirect) effect), why they did not use Sobel test, which is more accurate.

A6�Thank you very much for your professional suggestion. In our study, we primarily adopted the bootstrap method implemented in the mediation package, as it is more robust in finite samples and provides estimates of the indirect effect size as well as the proportion mediated.

To address the reviewer’s comment, we additionally conducted the Sobel test. The results also demonstrated a significant mediation effect (Z = −6.63, P < 0.0001), which is consistent with the bootstrap findings.

Both methods reached the same conclusion, supporting that BMI plays a significant partial mediating role in the relationship between eGDR and MetS. The corresponding sentence has been added in the revised manuscript at Lines 235–236: “Consistently, the Sobel test also confirmed the significance of the mediation pathway (Sobel Z = −6.63, P < 0.0001).”

Once again, we sincerely thank the reviewer for this valuable suggestion, which has made our manuscript more rigorous.

(Lines235-236)

Q7: The typing of the references in the text and in the references section need to recheck.

A7�Thank you very much for your meticulous review and for pointing out the issues regarding the references. I sincerely apologize for the oversight in both the in-text citations and the reference list. Following your valuable suggestion, I have carefully rechecked every citation in the text and ensured that each one exactly matches the corresponding entry in the reference list. In addition, I have thoroughly revised the reference section to strictly adhere to the journal’s formatting requirements, including citation style, punctuation, capitalization, and consistency. As required, PLOS uses the “Vancouver” style, as outlined in the ICMJE sample references, and I have ensured that all references now fully comply with this standard. I truly appreciate your thoughtful attention to such important details, which has significantly improved the overall quality and readability of the manuscript. Thank you again for your time, effort, and dedication to reviewing my work.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Marwan Al-Nimer, Editor

<p>Estimated Glucose Disposal Rate and Risk of Metabolic Syndrome: A Population-Based Study

PONE-D-25-26075R1

Dear Dr. Bohai Yu,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support .

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Marwan Salih Al-Nimer, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

No comments

Reviewers' comments:

Formally Accepted
Acceptance Letter - Marwan Al-Nimer, Editor

PONE-D-25-26075R1

PLOS ONE

Dear Dr. Yu,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Marwan Salih Al-Nimer

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .